Detection, evaluation, and management of iron-restricted erythropoiesis

Blood

Volumn 116, Issue 23, 2010, Pages 4754-4761

  Goodnough, Lawrence Tim ^a   Nemeth, Elizabeta ^b   Ganz, Tomas ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; BIOLOGICAL MARKER; FERRIC HYDROXIDE SUCROSE; FERRIECIT; FERRITIN; FERROUS GLUCONATE; FERROUS SULFATE; FERUMOXYTOL; HEMOGLOBIN; HEPCIDIN; INJECTAFER; IRON; IRON CHELATING AGENT; IRON DEXTRAN; PROTON PUMP INHIBITOR; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANEMIA; DRUG DOSE REDUCTION; DRUG RESPONSE; ERYTHROPOIESIS; HEMATOPOIESIS; HOMEOSTASIS; INFLAMMATION; IRON CHELATION; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON RESTRICTED ERYTHROPOIESIS; IRON THERAPY; IRON TRANSPORT; MALABSORPTION; MOLECULAR MECHANICS; PRIORITY JOURNAL; REVIEW;

EID: 78649753411     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-05-286260     Document Type: Review

References (78)

1. Goodnough LT (guest ed). The new age of iron: evaluation and management of iron-restricted erythropoiesis. Sem Hematol. 2009;46(4):325-327.
2. Brugnara C, Laufer MR, Friedman AJ, Bridges K, Platt O. Reticulocyte hemoglobin content (CHr): early indicator of iron deficiency and response to therapy. Blood. 1994;83(10):3100-3101. (Pubitemid 24142750)
3. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112(10):4292-4297.
4. Auerbach M, Goodnough LT, Picard D, Manaitis A. The role of intravenous iron in anemia management and transfusion avoidance. Transfusion. 2008;48(5):988-1000.
5. Finch CA. Perspective in iron metabolism. N Engl J Med. 1982;306(25):1520-1528.
6. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol. 2009;122(2-3):78-86.
7. Ashby DR, Gale DP, Busbridge M, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica. 2010;95(3):505-508.
8. Nemeth E. Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol (http://www.hindawi.com/journals/ah/). 2010;2010:750643. Accessed December 24, 2010.
9. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006;108(12):3730-3735. (Pubitemid 44864551)
10. Tanno T, Miller JL. Iron loading and overloading due to ineffective erythropoiesis. Adv Hematol (http://www.hindawi.com/journals/ah/). 2010;2010:358283. Accessed May 11, 2010.
11. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest. 2007;117(7):1926-1932.
12. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271-1276.
13. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):43-55.
14. Sasu BJ, Cooke KS, Arvedson TL, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood. 2010;115(17): 3616-3624.
15. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood. 2000; 96(3):823-833.
16. Freireich EJ, Miller A, Emerson CP, Ross JF. The effect of inflammation on the utilization of erythrocyte and transferrin bound radioiron for red cell production. Blood. 1957;12(11):972-983.
17. Zhang DL, Hughes RM, Ollivierre-Wilson H, Ghosh MC, Rouault TA. A ferroportin transcript that lacks an iron-responsive element enables duodenal and erythroid precursor cells to evade translational repression. Cell Metab. 2009;9(5): 461-473.
18. Keel SB, Abkowitz JL. The microcytic red cell and the anemia of inflammation. N Engl J Med. 2009; 361(19):1904-1906.
19. Ali MA, Luxton AW, Walker WH. Serum ferritin concentration and bone marrow iron stores: a prospective study. Can Med Assoc J. 1978;118(8): 945-946. (Pubitemid 8328105)
20. Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem. 1998;44(1):45-51.
21. Mercuriali F, Zanella A, Barosi G, et al. Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion. 1993;33(1):55-60.
22. Eschbach JW, Haley NR, Egrie JC, Adamson JW. A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects. Kidney Int. 1992;42(2):407-416.
23. Rockey DC, Cello JP. Evaluation of the gastrointestinal tract in patients with iron-deficiency anemia. N Engl J Med. 1993;329(23):1691-1695.
24. Raje D, Mukhtar H, Oshowo A, Ingham Clark C. What proportion of patients referred to secondary care with iron deficiency anemia have colon cancer? Dis Colon Rectum. 2007;50(8):1211-1214. (Pubitemid 47087476)
25. Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Laboratory Hematology. 2005;11(1):14-23.
26. Ferguson BJ, Skikne BS, Simpson KM, Baynes RD, Cook JD. Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia. J Lab Clin Med. 1992;119(4): 385-390.
27. Punnonen K, Irjala K, Rajamäki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997;89(3): 1052-1057.
28. Brugnara C. Use of reticulocyte cellular indices in the diagnosis and treatment of hematological disorders. Int J Clin Lab Res. 1998;28(1):1-11. (Pubitemid 128514814)
29. Brugnara C, Colella GM, Cremins J, et al. Effects of subcutaneous recombinant human erythropoietin in normal subjects: development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med. 1994;123(5):660-667.
30. Macdougall IC. What is the most appropriate strategy to monitor functional iron deficiency in the dialyzed patients on rhEPO therapy? Merits of percentage hypochromic red cells as a marker of functional iron deficiency. Nephrol Dial Transplant. 1998;13(4):847-849.
31. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002;100(10):3776-3781.
32. Castagna A, Campostrini N, Zaninotto F, Girelli D. Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics. 2010;73(3): 527-536.
33. Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol. 2009;4(8):1384-1387.
34. Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood. 2009;113(21):5277-5286.
35. Goodnough LT, Nissenson AR, Dubois RW. Anemia: not just an innocent bystander? Arch Intern Med. 2003;163(15):1400-1404.
36. Bonnar J, Goldberg A, Smith JA. Do pregnant women take their iron? Lancet. 1969;1(7592): 457-458.
37. Young MF, Glahn RP, Ariza-Nieto M, et al. Serum hepcidin is significantly associated with iron absorption from food and supplemental sources in healthy young women. Am J Clin Nutr. 2009; 89(2):533-538.
38. Ruivard M, et al. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol. 2009;50(6):1219-1225.
39. Annibale B, Capurso G, Chistolini A, et al. Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms. Am J Med. 2001;111(6):439-445.
40. Hershko C, Skikne B. Pathogenesis and management of iron deficiency anemia: emerging role of celiac disease, helicobacter pylori, and autoimmune gastritis. Semin Hematol. 2009;46(4):339-350.
41. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49(12): 2719-2728.
42. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med. 1987;316(2):73-7.
43. Sadjadi SA. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26(6):1000-1001.
44. Means RT Jr. Commentary: an anemia of chronic disease, after all? J Invest Med. 1999;47(5):203.
45. Adamson JW. Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: the many faces of inflammation. Adv Chron Kid Dis. 2009;16(2):76-82.
46. Skikne BS, Cook JD. Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Med. 1992; 120(5):746-751.
47. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26(6):41-46.
48. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis. 1995;25(3):433-439.
49. National Kidney Foundation KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 suppl 3):S11-S45.
50. Silverberg DS, Iaina A, Peer G, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996;27(2):234-238.
51. Coyne DW, Kapoian T, Suki N et al. Ferric gluconate is highly efficacious in anemia hemodialysis patients with high serum ferritin and low transferrin saturation. J Am Soc Nephrol. 2007;18(3): 975-984.
52. Gasche C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med. 1997;126(10):782-787.
53. Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med. 1996;334(10):619-623. (Pubitemid 26076567)
54. Weiss G, Houston T, Kastner S, Johrer K, Grunewald K, Brock JH. Regulation of cellular iron metabolism by erythropoietin: activation of iron-regulatory protein and upregulation of transferrin receptor expression in erythroid cells. Blood. 1997;89(2):680-687.
55. Delaby C, Pilard N, Goncalves AS, Beaumont C, Canonne-Hergaux F. Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. Blood. 2005;106(12): 3979-3984.
56. Auerbach M. Ferumoxytol as a newer, safer easier to administer intravenous iron: yes or no? Am J Kid Dis. 2008;52(5):826-829.
57. Fishbane J. Upper limit of serum ferritin: misinterpretation of the 2006 KDOQI anemia guidelines. Semin Dial. 2008;21(3):217-220.
58. Hillman RS, Henderson PA. Control of marrow production by the level of iron supply. J Clin Invest. 1969;48(3):454-460.
59. Hamstra RD, Block MH. Erythropoiesis in response to blood loss in man. J Appl Physiol. 1969; 27(4):503-507.
60. Crosby WH. The metabolism of hemoglobin and bile pigment in hemolytic disease. Am J Med. 1955;18(1):112-122.
61. Beutler E. The utilization of saccharated Fe59 oxide in red cell formation. J Lab Clin Med. 1958; 51(3):415-419.
62. Wood JK, Milner PF, Pathak UN. The metabolism of iron dextran given as a total-dose infusion to iron deficient Jamaican subjects. Br J Haematol. 1968;14(2):119-129.
63. Beamish MR, Davies AG, Eakins JD, Jacobs A, Trevett D. The measurement of reticuloendothelial iron release using iron-dextran. Br J Haematol. 1971;21(6):617-622.
64. Bentley DP, Williams P. Parenteral iron therapy in the anemia of rheumatoid arthritis. Rheumatol Rehabil. 1982;21(2):88-92. (Pubitemid 13097307)
65. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004; 22(7):1301-1307.
66. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12(2):231-242.
67. Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 2007;21(4):627-632. (Pubitemid 46444544)
68. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008;26(10):1611-1618.
69. Auerbach M, Silberstein P, Webb T, et al. Darbopoetin alfa 500mcg or 300mcg once every three weeks with or without iron in patients with chemotherapy induced anemia. Ann Oncol. 2008; 19(suppl 8):1-4.
70. Henry DH. Iron or vitamin B12 deficiency in anemic cancer patients prior to erythropoiesis-stimulating agent therapy. Community Oncologist. 2007;4:95-101.
71. Glaspy J, Crawford J, Van Steenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010;102(2):301-315.
72. United States Food and Drug Administration. Follow-up to the January 3, 2008 communication about an ongoing safety review on erythropoiesis- stimulating agents (ESAs) epoetin alfa (marketed as Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp). http://www.fda.gov/cder/drug/ infopage/RHE/default.htm. Accessed April 19, 2010.
73. National Comprehensive Cancer Network. Practice Guidelines I Oncology: Cancer - and Chemotherapy - Induced Anemia. V. 3.2009. http: //www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed October 21, 2010.
74. Gilson CR, Kraus TS, Hod EA, et al. A novel mouse model of red blood cell storage and post transfusion in vivo survival. Transfusion. http:// onlinelibrary.wiley.com/laneproxy.stanford.edu/ doi/10.1111/j.1537-2995.2009. 02173.x/pdf. Accessed October 21, 2010.
75. Jurado RL. Iron, infections, and anemia of inflammation. Clin Infect Dis. 1997;25(4):888-895.
76. Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nehrol. 2006;1:S19-S23.
77. Weiss G. Iron and immunity: A double edged sword. Eur J CLin Invest. 2002;32(suppl 1):70-78.
78. Crosby WH. The rationale for treating iron defi- ciency anemia. Arch Intern Med. 1984;144(3): 471-472.